ParcelBio takes on mRNA durability limits with $13m seed
US biotech startup ParcelBio has emerged from stealth with a $13 million seed financing aimed at overcoming one of the key biological constraints limiting broader use of mRNA medicines beyond vaccines and short-acting therapies.
The San Francisco-based company said the round was led by Breyer Capital, with participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital and ZAKA VC. The funding will support development of ParcelBio’s APEXm platform and help advance its preclinical pipeline, including an in vivo CAR-T program for autoimmune disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze